Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We appreciate the interest of van Schooneveld et al1 in our recent BJO article.2 Our small, retrospective chart review of retinitis pigmentosa (RP) patients treated off-label with valproic acid is only the first step in the process of understanding the potential utility of the drug for patients with this sight-threatening condition, for which there are no current therapeutic options.
The size and the scope of our article were limited by the nature of a retrospective chart review, which only allows analysis of follow-up that occurred within the defined time frame. Additional factors limiting the scope and length of the study included (1) the logistical and financial complexity …